Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in three upcoming investor conferences in January and February.
Continue reading here:
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences